Hepatitis B Vaccine (Recombinant) Market Size, Market Share, Data Analysis and Forecasts, 2023-2030 | Market Study by RationalStat

The global Hepatitis B Vaccine (Recombinant) market is expected to reach US$ 9.5 billion by 2030, with an annual growth rate of more than 5.6%.

Wilmington, Delaware, Nov. 09, 2023 (GLOBE NEWSWIRE) -- According to RationalStat’s most recent industry analysis, the Global Hepatitis B Vaccine (Recombinant) Market value is estimated at US$ 6.5 billion in 2023 and is expected to rise at a strong CAGR of over 5.6% over the forecast period of 2023-2030.

Market Definition, Market Scope, and Report Overview                                                              

Hepatitis B vaccine (recombinant) is a vaccination used to protect against hepatitis B virus (HBV) infection. It contains a little, harmless portion of the HBV virus (called a recombinant surface antigen) that stimulates the immune system to create antibodies against the virus.

Hepatitis B is a dangerous and sometimes fatal viral infection of the liver. The most effective method of preventing hepatitis B infections is vaccination. As global awareness of the disease and its prevention techniques grows, so does the need for hepatitis B vaccines.

  • According to a deep-dive market assessment by RationalStat, the global Hepatitis B Vaccine (Recombinant) market has been analyzed on the basis of market segments, including type, application, distribution channel and geography/regions (including North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa, and Asia Pacific). The report also offers global and regional market sizing for the historical period of 2019-2022 and the forecast period of 2023-2030.
  • Market intelligence for the global Hepatitis B Vaccine (Recombinant) market covers market sizes on the basis of market value (US$/EUR Million) and volume (Units) by various products/services/equipment, demand assessment across the key regions, customer sentiments, price points, cost structures, margin analysis across the value chain, financial assessments, historical and forecast data, key developments across the industry, import-export data, trade overview, components market by leading companies, etc.
  • In addition, the long-term sector and products/services 10-year outlook and its implications on the global Hepatitis B Vaccine (Recombinant) market. It also includes the industry's current state – Production Levels, Capacity Utilization, Tech quotient, etc. Key information will be manufacturing capacity by country, installed base, import volumes, market size, key players, market size, dynamics, market data, insights, etc.

Request A Customization- https://store.rationalstat.com/store/global-hepatitis-b-vaccine-recombinant-market/#tab-ux_global_tab

Global Hepatitis B Vaccine (Recombinant) Market: Segmental and Market Share Analysis

  • On the basis of distribution channel, the hospitals segment accounted for the highest market share in 2022. Owing to the large volume of product sales to the hospitals.
  • On the basis of application, new born/children segment is anticipated to dominate the global market as the first vaccination dose administered before the discharge of newborns from hospitals.

Report Synopsis

Report Metrics Details
Base Year 2023
Forecast Period 2023-2030
Base Year Market Size US$ 6.5 billion
Market Size Forecast US$ 9.5 billion
Growth Rate 5.6%
Dominant Segment Hospitals
Dominant Region North America
Key Market Drivers
  • Global immunization programs
  • Government initiatives and funding
  • Increased awareness
Companies Profiled
  • Bharat Biotech International Ltd.
  • CSL Ltd.
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • KM Biologics (Meiji Holdings Co., Ltd.)
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

Explore more about this report- https://store.rationalstat.com/store/global-hepatitis-b-vaccine-recombinant-market/#tab-ux_global_tab

Competition Analysis and Market Structure

Some leading players adopt various strategies in order to reinforce their market share and gain a competitive edge over other competitors in the market. Mergers & acquisitions, partnerships and collaborations, and product launches are some of the strategies followed by industry players. Some of the key developments in the global Hepatitis B Vaccine (Recombinant) market include.

  • In January 2021, Gilead Sciences, Inc. and Vir Biotechnology Inc cooperated to create a new combination medication for treating individuals infected with the hepatitis B virus. The primary goal of this collaboration is to explore various potential treatment combinations for the development of a new hepatitis B vaccine.

Some of the prominent players and suppliers operating and contributing significantly to the global Hepatitis B Vaccine (Recombinant) market growth include Bharat Biotech International Ltd., CSL Ltd., Dynavax Technologies Corp, Emergent BioSolutions Inc., GlaxoSmithKline PLC, KM Biologics (Meiji Holdings Co., Ltd.), LG Chem Ltd., Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.

Get A Free Sample- https://store.rationalstat.com/store/global-hepatitis-b-vaccine-recombinant-market/#tab-ux_global_tab

RationalStat has segmented the global Hepatitis B Vaccine (Recombinant) market based on type, application, distribution channel and region

  • Global Hepatitis B Vaccine (Recombinant) Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Type
  • 10mcg/ml
  • 10mcg/0.5ml
  • Global Hepatitis B Vaccine (Recombinant) Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Application
  • Newborn/Children
  • Adult
  • Global Hepatitis B Vaccine (Recombinant) Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Government Supplies
  • Global Hepatitis B Vaccine (Recombinant) Market Value (US$ Million), Volume (Units), and Market Share (2019-2030) Analysis by Region
    • North America Hepatitis B Vaccine (Recombinant) Market
      • US
      • Canada
    • Latin America Hepatitis B Vaccine (Recombinant) Market
      • Brazil
      • Mexico
      • Rest of Latin America
    • Western Europe Hepatitis B Vaccine (Recombinant) Market
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe Hepatitis B Vaccine (Recombinant) Market
      • Russia
      • Poland
      • Hungary
      • Other CIS Countries
      • Rest of Eastern Europe
    • Asia Pacific Hepatitis B Vaccine (Recombinant) Market
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • ASEAN
        • Indonesia
        • Thailand
        • Philippines
        • Vietnam
        • Malaysia
        • Rest of ASEAN
      • Rest of Asia Pacific
    • Middle East & Africa Hepatitis B Vaccine (Recombinant) Market
      • GCC
        • Saudi Arabia (KSA)
        • United Arab Emirates (UAE)
        • Rest of the GCC
      • South Africa
      • Nigeria
      • Turkey
      • Rest of the Middle East & Africa

For more information about this report- https://store.rationalstat.com/store/global-hepatitis-b-vaccine-recombinant-market/

Key Questions Answered in the Hepatitis B Vaccine (Recombinant) Report:

  • What will be the market value of the global Hepatitis B Vaccine (Recombinant) market by 2030?
  • What is the market size of the global Hepatitis B Vaccine (Recombinant) market?
  • What are the market drivers of the global Hepatitis B Vaccine (Recombinant) market?
  • What are the key trends in the global Hepatitis B Vaccine (Recombinant) market?
  • Which is the leading region in the global Hepatitis B Vaccine (Recombinant) market?
  • What are the major companies operating in the global Hepatitis B Vaccine (Recombinant) market?
  • What are the market shares by key segments in the global Hepatitis B Vaccine (Recombinant) market?  

Running a year End discount of 20%-https://store.rationalstat.com/store/global-hepatitis-b-vaccine-recombinant-market/#tab-ux_global_tab

Explore Our Trending Reports

Research Methodology

RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.

RationalStat combines a mix of secondary sources as well as primary research to assess the market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:

  • Defining the problem by understanding the type of market and data required by the client.
  • Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
  • Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
  • Evaluating and analyzing the data by referring to data sources utilized and leveraged.
  • Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.

Download Key Insights and Market Data - Raise a Query

About RationalStat LLC                    

RationalStat is an end-to-end global market intelligence and consulting company that provides comprehensive market research reports, customized strategy, and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.

RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, valuations and advisory, financial research, due diligence, procurement and supply chain research, data analytics, and analytical dashboards.


RationalStat LLC

Kimberly Shaw,

Content and Press Manager


US Phone: +1 302 803 5429

UK Phone:  +44 203-287-1245

LinkedIn | FacebookTwitterInstagramPinterest